Evidence map›Paper›PMID 40391688›Full record

Trial reportHuman vaccines & immunotherapeutics2025

Immunogenicity and safety of hepatitis A vaccine at different vaccination intervals among adults aged 18 years and above: Interim results.

Lin Chang, Zhen Li, Yang Liu, Siping Fei, Ling Zhao, Jun Li, Wenjing Huang, Yang Yang, Ling Tuo, Boyu Feng and 4 more

Abstract readRandomized Controlled Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Human vaccines & immunotherapeutics, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Traveling with chronic viral hepatitis.Tropical diseases, travel medicine and vaccines · 2026
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Lin ChangDepartment of Immunization, Liaoning Provincial Center for Disease Control and Prevention, Shenyang, Liaoning, China.
Zhen LiMedical Affairs Department, Sinovac Biotech Ltd, Beijing, China.
Yang LiuDepartment of Immunization, Dandong City Center for Disease Control and Prevention, Dandong, Liaoning, China.
Siping FeiDepartment of Immunization, Liaoning Provincial Center for Disease Control and Prevention, Shenyang, Liaoning, China.
Ling ZhaoDepartment of Immunization, Dandong City Center for Disease Control and Prevention, Dandong, Liaoning, China.
Jun LiDepartment of Quanlity Control, Sinovac Biotech Ltd, Beijing, China.
Wenjing HuangInstitute of Preventive Medicine, China Medical University, Shenyang, Liaoning, China.
Yang YangInstitute of Preventive Medicine, China Medical University, Shenyang, Liaoning, China.
Ling TuoDepartment of Statistics, Sinovac Biotech Ltd, Beijing, China.
Boyu FengDepartment of Immunization, Liaoning Provincial Center for Disease Control and Prevention, Shenyang, Liaoning, China.
Xuemei WuDepartment of Quanlity Control, Sinovac Biotech Ltd, Beijing, China.
Yanwei ZhaoMedical Affairs Department, Sinovac Biotech Ltd, Beijing, China.
Jing LiDepartment of Quanlity Control, Sinovac Biotech Ltd, Beijing, China.
Xing FangDepartment of Immunization, Liaoning Provincial Center for Disease Control and Prevention, Shenyang, Liaoning, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

This study aims to evaluate the immunogenicity and safety of hepatitis A vaccine administered with one or two doses among adults. Participants aged 18 y and above were recruited, with blood samples collected prior to vaccination for anti-HAV antibodies screening. All participants received a single dose of hepatitis A vaccine. Participants who tested negative for anti-HAV antibodies before vaccination were randomly assigned to four groups to receive the second dose at different intervals. Blood samples were collected for antibody testing. Adverse events were reported within 28 d after each vaccination for safety assessment. A total of 1,042 participants were included in study analysis. The seroprevalence of anti-HAV antibodies was 52.56%, with the lowest seroprevalence observed among adults aged 36-40 y. The overall seroconversion rate 1 month after the first dose of hep A vaccine was 67.68%. For participants in group A, the second dose was administered at a 6-month interval, both the seropositivity and seroconversion rates reached 100%, with a GMC of 3602.44 IU/L 1 months after the second vaccination. Difference of GMCs had no statistical significance across age groups. The incidence of adverse reactions (ARs) within 28 d after second vaccination in group A was 3.85%. No serious adverse events (SAEs) related to vaccination were reported. This interim analysis highlights the susceptibility of adults to hepatitis A virus (HAV). One or two doses of hepatitis A vaccine demonstrated good immunogenicity and safety in adults.

Indexed as

Hepatitis AHepatitis A AntibodiesHepatitis A VaccinesImmunization ScheduleImmunogenicity, VaccineAdolescentAdultAgedDrug-Related Side Effects and Adverse ReactionsFemaleHumansMaleMiddle AgedSeroconversionSeroepidemiologic StudiesVaccinationHepatitis A AntibodiesHepatitis A VaccinesadultsHepatitis Ahepatitis A vaccineimmunogenictiysafetyseroconversion rateseroprevalence

Identifiers

PMID40391688
PMCPMC12101589

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.